| 货号 | 16707-25mg |
| 描述 | Janus kinases (JAKs) are non-receptor kinases that mediate signaling through cytokine receptors, often to members of the signal transducer and activator of transcription (Stat) family.1 Baricitinib is an orally bioavailable, reversible inhibitor of JAK1 and JAK2 (IC50s = 5.9 and 5.7 nM, respectively) that has been shown to inhibit cytokine-induced phosphorylation of STAT3 in healthy human volunteers.2,3,4 It has potential application in various inflammatory disorders, including rheumatoid arthritis.2,4 |
| 别名 | INCB 028050;LY3009104; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Yamaoka, K.,Saharinen, P.,Pesu, M., et al. The janus kinases (Jaks). Genome Biology 5(12), 1-6 (2004). 2.Fridman, J.S.,Scherle, P.A.,Collins, R., et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: Preclinical characterization of INCB028050. Journal of Immunology 184(9), 5298-5307 (2010). 3.Migita, K.,Izumi, Y.,Torigoshi, T., et al. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Clinical and Experimental Immunology 174(3), 356-363 (2013). 4.Shi, J.G.,Chen, X.,Lee, F., et al. The pharmacokinetics, pharmacodynamics and safety of baricitinib, an oral JAK ½ inhibitor, in healthy volunteers. Journal of Clinical Pharmacology (2014). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 371.4 |
| 分子式 | C16H17N7O2S |
| CAS号 | 1187594-09-7 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |